BonAlive Biomaterials Ltd, an emerging leader in the field of implantable medical devices for bone regeneration, has launched a patented, ready-to-use and mouldable version of their osteostimulative BonAlive bioactive glass bone regeneration technology.

The launch of the osteostimulative BonAlive putty is an important milestone in the commercialization strategy of the BonAlive product family. The current BonAlive granules products have been approved for orthopaedic use since 2006 and for bone cavity filling in the treatment of chronic osteomyelitis since March 2011.

"As an extension to the BonAlive granules product line, the BonAlive putty will significantly strengthen our position in the trauma and spine market as surgeons are increasingly demanding products that are both easy and ready-to-use while delivering a solid clinical outcome," said Dr Fredrik Ollila, CEO of BonAlive Biomaterials Ltd.

BonAlive Biomaterials Ltd provides world-leading biomaterial solutions for the treatment of chronically infected bone. BonAlive® products are available in Europe, Middle East, Asia-Pacific, Africa, Brazil and the USA through a professional distributor network. The clinical use of BonAlive bioactive glass is supported by a twenty year research history including several randomized prospective trials in the field of spine, benign bone tumour and trauma surgery.